PMID: 9442813Jan 27, 1998Paper

A commentary on 10 years of aldose reductase inhibition for limited joint mobility in diabetes

Journal of Diabetes and Its Complications
R P EatonJ M Bicknell

Abstract

This investigation examines the clinical response to long-term treatment of the diabetic syndrome of limited joint mobility (LJM) using an aldose reductase inhibitor (ARI) in comparison to historical controls, and proposes a potential role of aldose reductase (AR) genotype and expression in the clinical response to ARI. Clinical parameters, including quantitative hand movement and electromyogram, were followed over a decade of continuous ARI treatment with sorbinil (400 mg/day) in two patients with insulin-dependent diabetes mellitus (IDDM) and severe compromising LJM, and compared to the published 10-year prospective investigation of untreated IDDM diabetic patients with LJM. Both subjects were homozygous for the Z-2 AR allele (A-C)23 that has been linked with microvascular complications of DM. Cellular AR mRNA/beta-actin ratios for both treated patients while on ARI therapy were approximately one-half the value observed in untreated patients with the complications of nephropathy or neuropathy. This is the longest reported experience of ARI intervention for any diabetic complication, documenting sustained correction of LJM, lack of side effects, and a potential molecular basis for the therapeutic response.

References

Oct 1, 1975·Diabetes·C R HamlinJ H Luschin
Feb 1, 1977·Biopolymers·S NomuraE Baer
Mar 11, 1992·The American Journal of Physiology·F L SmardoA Garcia-Perez
Jul 1, 1992·The Journal of Clinical Investigation·W A Border, E Ruoslahti
Sep 1, 1985·Diabetic Medicine : a Journal of the British Diabetic Association·M Mengistu, J Abdulkadir
Mar 8, 1985·JAMA : the Journal of the American Medical Association·R P EatonA Harsh
Apr 19, 1973·The New England Journal of Medicine·K H Gabbay
Nov 1, 1971·Metabolism: Clinical and Experimental·Y JungT S Danowski
Feb 1, 1980·European Journal of Clinical Investigation·S BazinA Delaunay
Jan 1, 1995·The Journal of Hand Surgery·M ChammasY Allieu
Aug 1, 1994·Journal of Internal Medicine·P E ArkkilaJ S Viikari
Nov 1, 1993·Diabetic Medicine : a Journal of the British Diabetic Association·D R McCanceL Kennedy

❮ Previous
Next ❯

Citations

May 5, 2004·Best Practice & Research. Clinical Rheumatology·Perttu E T Arkkila, Jean-Francois Gautier
Jul 11, 2006·Clinics in Dermatology·Intekhab Ahmed, Barry Goldstein
Jan 5, 2001·Expert Opinion on Investigational Drugs·P J Oates, B L Mylari
Aug 13, 2011·Diabetes Research and Clinical Practice·Hisham Y Al-MatubsiMaher Salim
Jan 2, 2007·Clinical Orthopaedics and Related Research·Odette LaneuvilleGuy Trudel
Dec 18, 2004·Current Opinion in Rheumatology·Dana Jacobs-Kosmin, Raphael J DeHoratius

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.